Skip to main content

The Phase III Cancer Clinical Trial

  • Chapter
Anticancer Drug Development Guide

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 428 Accesses

Abstract

The Phase III clinical trial is a randomized, comparative, often multi-institutional study addressed to a quantitative question. It is the cadillac of clinical trials. When properly applied, it is highly effective in comparing new treatment and standard (control) therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fisher B, Redmond CK, Wolmark N, et al. Longterm results from NSABP trials of adjuvant therapy for breast cancer. In: Salmon, SE, ed. Adjuvant Chemotherapy of Cancer, V. Orlando: Grane and Stratton. 1987: 283–295.

    Google Scholar 

  2. Bonadonna G, Brusamolia E, Rossi A, et al. Combination chemotherapy as adjuvant treatment in opearble breast cancer. N Eng J Med 1976; 294: 415.

    Article  Google Scholar 

  3. Zelen M. The theory and practice of clinical trials. In: Holland, Frei, Bast, Kufe, Morton, Weichselbaum, Williams and Wilkins. Cancer Medicine, 3rd ed. 1992: 340–361.

    Google Scholar 

  4. Goldin A, Venditti J, Humphreys SR, et al. Influence of the concentration of leukemic inoculum on the effectiveness of treatment. Science 1956; 123: 840.

    Article  PubMed  CAS  Google Scholar 

  5. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic and immune therapy. Lancet 1992; 339:1–15, 72–85.

    Google Scholar 

  6. Goorin A, Abelson H, Frei E III. Osteosarcoma: Fifteen years later. N Eng J Med 1985; 313: 1637–1643.

    Article  CAS  Google Scholar 

  7. Wood W, Korzan A, Cooper R, et al. Dose and dose intensity for adjuvant chemotherapy for stage II, node positive, breast cancer. N Eng J Med 1994; 330: 1253.

    Article  CAS  Google Scholar 

  8. Fisher, R, Gaynor ER, Dahlberg S, et al. Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non—Hodgkin’s lymphoma. N Eng J Med 1993; 328: 1002–1006.

    Article  CAS  Google Scholar 

  9. Frei E III, Freireich EJ. The clinical cancer researcher—still an embattled species. J Clin Onc 1993; 11: 1693–1671.

    Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Frei, E. (1997). The Phase III Cancer Clinical Trial. In: Teicher, B.A. (eds) Anticancer Drug Development Guide. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-4615-8152-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-8152-9_15

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4615-8154-3

  • Online ISBN: 978-1-4615-8152-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics